RGCNasdaqMedicinal Chemicals & Botanical Products
Regencell Bioscience Holdings Ltd
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 7, 2026
$10.05+0.46 (+4.80%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.36 (−42.27%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.70M
- EPS, diluted
- -$2.37
Nine years at a glance
Fiscal years 2018 to 2026, USD
Operating income
-$11.72M
Net income
-$11.70M
EPS, diluted
-$2.37
Free cash flow
–
Reported period